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Background
HIV-2 infection is characterized by an attenuated disease
course in most patients, which may reflect viraemia con-
trol by an efficient immune response. However, there is
little information on the breadth, magnitude, or specifi-
city of cellular immune responses to the proteome and
their relationship to viral control.
Methods
105 freshly separated PBMCs from 64 members of a well-
described community-based HIV-2 cohort (Caio, Guinea
Bissau) were used in ex vivo IFNg ELISpot assays. 424 pep-
tides spanning the HIV-2 proteome were divided into 3 ×
24 pools in a 3-dimensional matrix (16–20 peptides/
pool, 2 μg/ml per peptide).
Results
All HIV-2 gene products induced IFNg responses, with
Gag being targeted most frequently (89% of patients). The
total proteome response inversely correlated with HIV-2
VL (p < 0.01) and this relationsAhip was due to targeting
Gag (p < 0.01). Patients with VL ≤ 100 (N = 31) had a
greater median gag-specific response (1120 vs 385 SFU, p
< 0.01) than patients with VL ≥ 100 (N = 33). Responses
to a single Gag peptide (recognized by >30% of patients)
correlated with low VL (p = 0.05).
Conclusion
There is a strong relationship between HIV-2 VL and IFNg
responses. VL ≤ 100 correlates with targeting Gag, with the
6 most frequently recognized peptides originating from a
highly conserved region spanning 149 aa, suggesting that
immune responses to this region play a role in HIV-2
viraemia control.
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